« Return to News | Miscellaneous

Anapharm Under New Leadership

Friday, February 23, 2007 02:01 PM

Princeton, N.J.-based PharmaNet Development Group is showing more signs of positive change as it attempts to move forward after troubled times. It announced this week that it appointed Johane Boucher-Champagne president and chief executive of its Anapharm unit, a phase I and bioequivalencey business based in Quebec City, Canada.

She has been acting chief executive since December and began working at Anapharm as its chief operating officer in 1998. Boucher-Champagne will replace Marc LeBel who founded Anapharm in 1996. Anapharm was acquired by SFBC International, now PharmaNet, in 2002.

In August 2006—after emerging from a year of legal and financial blows and bad publicity concerning recruitment of illegal immigrants in phase I trials—SFBC changed its name to PharmaNet Development Group, a company it acquired in 2004 for $245 million in cash.

The company closed its Miami facility, effectively ending its phase I and bioequivalencey business in the U.S. The Anapharm group kept its name and became the company's only remaining early stage unit. It operates solely in Canada.

Anapharm had its own round of controversy last year after at least 19 subjects were exposed to, and nine patients tested positive for tuberculosis (TB) while enrolled in a non-TB related trial.

A 37-year-old man with an active case of the disease was included in the trial, and there were reports that he was kept in the on-site study with subjects despite visible symptoms of illness. The issue prompted Health Canada to require new patients be screened for contagious diseases and monitored for specific symptoms.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.